DOCTIFY RAISES €6.3M FOR HEALTHCARE REVIEW PLATFORM
London-based healthcare review platform Doctify has raised an additional €6.3M in a round of funding. The investment was led by Keen Venture Partners and existing investors including Amadeus Capital, Guinness Asset Management and Tom Teichman.
Doctify has now raised an overall investment of €16.8M to expand its platform, which allows patients to review, choose and book appointments with doctors.
The platform uses SaaS software to provide insights and analytics into the care they provide and enables patients to receive real-time feedback for a hospital, clinic or doctor for a condition or procedure.
Healthcare providers are then able to collect and digitise patient feedback and publish it through external and internal channels.
Neovasc Inc.: Neovasc Provides Tiara TA Update
Vancouver, British Columbia and Minneapolis, Minnesota (Newsfile Corp. - April 16, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ( Neovasc or the Company ), today announced that the Tiara Transapical system ( Tiara TA ) will be unable to receive a European CE mark under the current Medical Device Directive regulations ( MDD ) ending on May 26, 2021. The Company is collaborating with its European Notified Body (the Notified Body ) on potential next steps.
Neovasc has been working with its Notified Body for more than a year to obtain a decision on a CE Mark for Tiara TA, including an ongoing exchange of additional information beyond the original submission. The Company has determined that it will be unable to provide the additional information required by the Notified Body, which includes further testing data, before the current MDD regulations end next month.
DexCom, Inc.: Dexcom Starts Direct Distribution in the Netherlands
Dexcom G6 CGM means no more fingersticks for people with diabetes or Dexcom receiver
Share glucose levels with up to five followers for additional remote monitoring
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distribution collaboration with Zkope Healthcare and is now selling the Dexcom G6 CGM system directly throughout the Netherlands. At Dexcom, we are committed to expanding access to CGM for people with diabetes around the world. Being direct in market represents a significant step forward in allowing us to provide the best standard of care in diabetes management, bringing CGM technology to patients and healthcare providers across the Netherlands, said Erik Bjorkman, general manager and senior vice president for EMEA at Dexcom.
How To Navigate Clinical Data Per EU MDR
By Matthias Fink, MD, TÜV SÜD America
In May 2017, the European Medical Devices Regulation (MDR) 2017/745 was published to replace the current Medical Device Directive (MDD) and the Active Implantable Medical Device Directive (AIMDD). In April 2020, the European Parliament adopted the European Commission’s proposal to postpone the Date of Application (DoA) of the MDR by one year, and as such, the new DoA is May 26, 2021. It is worth noting that the end of the transition period for MDD and AIMDD certificates remains May 26, 2024, thus reducing the timeline for manufacturers to get their MDR certificates from four to three years.
Dexcom Starts Direct Distribution in the Netherlands streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.